August 2026
1. PINEDA JE, Minowa T, Shen L, Zhou Y, et al
   Antigen presentation requirements for effective cDC1-based cancer immunotherapy.
   J Immunol. 2026;215:vkag198.
   

   >> Share

   
   
2. HASSAN NT, Loffler J, Sachs Dos Santos A, Wohlfarth J, et al
   Immunotherapy of malignant melanoma using T cell-activating microbeads.
   J Immunol. 2026;215:vkag191.
   

   >> Share

   
   July 2026
3. DE JOODE K, Balcioglu HE, van Brakel M, Lopez-Cascales MT, et al
   Long-term survivors of melanoma after anti-PD-1 therapy demonstrate on-treatment increase in abundance of 4-1BB+ CD4 T cells in blood.
   J Immunol. 2026;215:vkag171.
   

   >> Share

   
   June 2026
4. PAL P, Wahi P, Paul S, Meitei HT, et al
   Complement C3 deficiency increases the effector and cytotoxic functions of NK cells and suppresses tumor growth.
   J Immunol. 2026;215:vkag157.
   

   >> Share

   
   
5. MACY AM, Herrmann LM, Thornley EM, Adams AC, et al
   MHC class II on melanoma cells regulates the anti-tumor T cell response.
   J Immunol. 2026;215:vkag158.
   

   >> Share

   
   May 2026
6. TURNQUIST A, Javaid A, Wilkins OM, Kolling Iv F, et al
   PI3Kdelta inhibition alters CD8 T cell differentiation and reprograms the tumor microenvironment following adoptive immunotherapy.
   J Immunol. 2026;215:vkag108.
   

   >> Share

   
   March 2026
7. ONCUL S, Lee H, Singh S, Yee C, et al
   B cell depletion promotes melanoma tumor growth in a CD4+ T cell-dependent manner.
   J Immunol. 2026;215:vkag004.
   

   >> Share

   
   January 2026
8. HUANG P, Wang H, Guan X, Pu R, et al
   UTY coordinates with UTX to repress NK cell development and maturation in males.
   J Immunol. 2026;215:vkaf248.
   

   >> Share

   
   December 2025
9. GIRARD M, Yu T, Batista NV, Yeung KKM, et al
   STING agonists drive recruitment and intrinsic type I interferon responses in monocytic lineage cells for optimal anti-tumor immunity.
   J Immunol. 2025;214:3634-3646.
   

   >> Share

   
   October 2025
10. LIU M, Dhakal H, Li H, Murakami M, et al
    Prostaglandin D2 axis impairs immunity against melanoma via dendritic cells and gammadelta T cells in middle-aged mice.
    J Immunol. 2025 Oct 28:vkaf288. doi: 10.1093.
    

    >> Share

    
    
11. REN Y, Ballard DJ, Kumar A, Song AF, et al
    eEF2K promotes immune evasion in melanoma via Cyclin D1-mediated stabilization of PD-L1.
    J Immunol. 2025 Oct 16:vkaf278. doi: 10.1093.
    

    >> Share

    
    
12. REINARTZ DM, Escamilla-Rivera V, Shao M, Tribble SL, et al
    Impact of absent in melanoma 2 on head and neck squamous cell carcinoma development.
    J Immunol. 2025 Oct 3:vkaf224. doi: 10.1093.
    

    >> Share

    
    August 2025
13. TANEGASHIMA K, Esashi E, Ishida K, Kotaki A, et al
    CXCL14 is an essential modulator of TLR9 agonist-induced antitumor immune responses.
    J Immunol. 2025;214:2076-2086.
    

    >> Share

    
    September 2024
14. DIAMANTOPOULOS N, Li J, Bouchard A, Joumier L, et al
    ICOS-expressing Regulatory T Cells Influence the Composition of Antitumor CTL Populations.
    J Immunol. 2024;213:753-762.
    

    >> Share

    
    July 2024
15. ADAM K, Lipatova Z, Abdul Ghafoor Raja M, Mishra AK, et al
    Cutting Edge: LAG3 Dimerization Is Required for TCR/CD3 Interaction and Inhibition of Antitumor Immunity.
    J Immunol. 2024;213:7-13.
    

    >> Share

    
    December 2023
16. PEIL J, Vossen C, Bock F, Clahsen T, et al
    Combined Osteopontin Blockade and Type 2 Classical Dendritic Cell Vaccination as Effective Synergetic Therapy for Conjunctival Melanoma.
    J Immunol. 2023 Dec 15:ji2300063. doi: 10.4049/jimmunol.2300063.
    

    >> Share

    
    
17. SINGH S, Xiao Z, Bavisi K, Roszik J, et al
    Corrections: IL-1alpha mediates innate and acquired resistance to immunotherapy in melanoma.
    J Immunol. 2023 Dec 13:ji2300689. doi: 10.4049/jimmunol.2300689.
    

    >> Share

    
    July 2023
18. THOMPSON B, Strange A, Amato CM, Hester-McCullough J, et al
    CD4 Phenotypes Are Associated with Reduced Expansion of Tumor-Infiltrating Lymphocytes in Melanoma Patients Treated with Adoptive Cell Therapy.
    J Immunol. 2023 Jul 19:ji2300250. doi: 10.4049/jimmunol.2300250.
    

    >> Share

    
    March 2023
19. ALAM MM, Gower T, Jiang M, Oppenheim JJ, et al
    A Therapeutic Vaccine in Combination with Cyclic GMP-AMP Cures More Differentiated Melanomas in Mice.
    J Immunol. 2023 Mar 22:ji2200371. doi: 10.4049/jimmunol.2200371.
    

    >> Share

    
    July 2021
20. CARLSON PM, Mohan M, Patel RB, Birstler J, et al
    Optimizing Flow Cytometric Analysis of Immune Cells in Samples Requiring Cryopreservation from Tumor-Bearing Mice.
    J Immunol. 2021;207:720-734.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share